Bayer Healthcare announced that the FDA has accepted its New Drug Application (NDA) for filing and has granted priority review of Radium Ra 223 Dichloride (radium-223) for the treatment of ...

Remarkably, even though radioactivity is a threat to life, scientists can control and use it to diagnose and treat diseases – including cancers. If the radiation is delivered precisely to where cancer ...

Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has received marketing authorisation from the European Commission for Xofigo ® (radium Ra 223 dichloride) solution ...

U.S. FDA Grants Priority Review to Bayer's Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases WAYNE, N.J., Feb. 13, 2013 /PRNewswire/ -- Bayer HealthCare ...

Oslo, Norway, 20 June 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, today celebrates the official opening of its commercial production ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that new NUBEQA ® (darolutamide) and Xofigo ® (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology ...

Bayer announced today that new research findings on Xofigo ® (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical ...

(MENAFN- Market Press Release) March 29, 2025 4:01 am - Brazil, India, and Indonesia are the fastest growing demand hubs within the $459.1 million Radium Ra 223 Dichloride market and expected to grow ...

Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH). This is an ASCO Meeting Abstract from the 2014 Quality Care Symposium.

Using lasers with precisely tuned frequency, λ, physicists control rotational states of radium monofluoride molecules and excite specific rotational levels, characterized by the quantum number, J.